Latest glioblastoma multiforme Stories
Patients Too Sick for Enrollment in Phase III Trial for Newly Diagnosed GBM BETHESDA, Md., March 27, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
NEW YORK, March 25, 2015 /PRNewswire/ -- The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according
The co-chairs announce the Northwestern Brain Tumor Institute Minds Matter 2015 Fundraising Gala for May 1, 2015 CHICAGO, March 24, 2015 /PRNewswire-USNewswire/ -- One day in 2009,
BETHESDA, Md., March 24, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies
LOS ANGELES and MAASTRICHT, The Netherlands, March 19, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Oncology team hopeful their research will help address major challenges in treating high-grade gliomas, including glioblastoma HACKENSACK, N.J., March 18, 2015 /PRNewswire-USNewswire/
- Duke Cancer Institute researchers publish Phase 1/2 study results in Nature providing human proof-of-concept for new solid tumor target and "immune pre-conditioning" approach to cancer immunotherapy.
Nature to publish findings of tetanus shot booster with immunotherapy Chicago, Ill.
LOS ANGELES, March 10, 2015 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the twelve
ICT-107 Poised to Begin Phase 3 Registration Trial in Second Half of 2015; Business Update Conference Call to be Held on March 12, 2015 LOS ANGELES, March 9, 2015 /PRNewswire/ -- ImmunoCellular